(Q44516155)

3 December 2017

Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination (English)

1 reference

3 December 2017

1 reference

Anastasios G P Konstas

1

object named as

Anastasios G P Konstas

1 reference

3 December 2017

Panayiotis Papapanos

2

1 reference

3 December 2017

Ioannis Tersis

3

1 reference

3 December 2017

Dimitra Houliara

4

1 reference

3 December 2017

William C Stewart

5

1 reference

3 December 2017

1 July 2003

1 reference

3 December 2017

1 reference

3 December 2017

110

1 reference

3 December 2017

7

1 reference

3 December 2017

1357-1360

1 reference

The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Comparison of latanoprost, brimonidine and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Prostaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Latanoprost 0.005% and anterior segment uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

Perspectives in the medical treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900404-4

7 January 2021

10.1016/S0161-6420(03)00404-4

Identifiers

DOI

1 reference

3 December 2017

1 reference